Experimental combo targets Hard-to-Treat brain tumors
NCT ID NCT07422363
First seen Feb 24, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This early-phase trial tests a new two-drug combination for people whose glioblastoma (a severe brain cancer) has returned after initial treatment. The study combines a radioactive antibody that seeks out cancer cells with an immunotherapy drug that helps the immune system fight the tumor. The main goals are to find the safest dose and identify side effects in about 30 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.